263 related articles for article (PubMed ID: 7973765)
1. The clinical pharmacokinetics of vinorelbine (Navelbine).
Wargin WA; Lucas VS
Semin Oncol; 1994 Oct; 21(5 Suppl 10):21-7. PubMed ID: 7973765
[TBL] [Abstract][Full Text] [Related]
2. Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer.
Winer EP; Chu L; Spicer DV
Semin Oncol; 1995 Apr; 22(2 Suppl 5):72-8; discussion 78-9. PubMed ID: 7740337
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design.
Vokes EE; Drinkard LC; Samuels BL; Hoffman PC; Watson S; Bitran JD; Haraf DJ; Ferguson MF; Golomb HM
Semin Oncol; 1994 Oct; 21(5 Suppl 10):79-83; discussion 83-4. PubMed ID: 7973772
[TBL] [Abstract][Full Text] [Related]
4. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
[TBL] [Abstract][Full Text] [Related]
5. Oral versus intravenous vinorelbine: clinical safety profile.
Gebbia V; Puozzo C
Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
[TBL] [Abstract][Full Text] [Related]
6. Vinorelbine (Navelbine)--a new agent for the treatment of non-small cell lung cancer: a summary.
Coltman CA
Semin Oncol; 1994 Oct; 21(5 Suppl 10):1-3. PubMed ID: 7973763
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer.
Souquet PJ; Fournel P; Bohas CH; Fortune IC; Chatte G
Semin Oncol; 1996 Apr; 23(2 Suppl 5):8-10. PubMed ID: 8610239
[TBL] [Abstract][Full Text] [Related]
8. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
[TBL] [Abstract][Full Text] [Related]
9. Update: vinorelbine (navelbine) in non-small cell lung cancer.
Crawford J
Semin Oncol; 1996 Apr; 23(2 Suppl 5):2-7. PubMed ID: 8610232
[TBL] [Abstract][Full Text] [Related]
10. Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study.
Vokes EE; Haraf DJ; Masters GA; Hoffman PC; Drinkard LC; Ferguson M; Olak J; Watson S; Golomb HM
Semin Oncol; 1996 Apr; 23(2 Suppl 5):48-52. PubMed ID: 8610237
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer.
Hillner BE; Smith TJ
Semin Oncol; 1996 Apr; 23(2 Suppl 5):25-30. PubMed ID: 8610234
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of radiation therapy by vinorelbine (Navelbine) in non-small cell lung cancer.
Edelstein MP; Wolfe LA; Duch DS
Semin Oncol; 1996 Apr; 23(2 Suppl 5):41-7. PubMed ID: 8610236
[TBL] [Abstract][Full Text] [Related]
13. Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer: a preliminary report.
Vokes EE; Rosenberg R; Jahanzeb M; Craig J; Gralla R; Belani C; Jones S; Bigley J; Hohneker J
Semin Oncol; 1994 Oct; 21(5 Suppl 10):35-8; discussion 38-41. PubMed ID: 7973767
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
Rowinsky EK; Noe DA; Trump DL; Winer EP; Lucas VS; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Ettinger DS
J Clin Oncol; 1994 Sep; 12(9):1754-63. PubMed ID: 8083697
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics of vinorelbine.
Levêque D; Jehl F
Clin Pharmacokinet; 1996 Sep; 31(3):184-97. PubMed ID: 8877249
[TBL] [Abstract][Full Text] [Related]
16. Summary of data from in vitro and phase I vinorelbine (Navelbine) studies.
Burris HA; Fields S
Semin Oncol; 1994 Oct; 21(5 Suppl 10):14-9; discussion 19-20. PubMed ID: 7973764
[TBL] [Abstract][Full Text] [Related]
17. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group.
Johansen M; Kuttesch J; Bleyer WA; Krailo M; Ames M; Madden T
Clin Cancer Res; 2006 Jan; 12(2):516-22. PubMed ID: 16428494
[TBL] [Abstract][Full Text] [Related]
18. Vinorelbine tartrate (Navelbine): drug profile and nursing implications of a new vinca alkaloid.
Brogden JM; Nevidjon B
Oncol Nurs Forum; 1995 May; 22(4):635-46. PubMed ID: 7675666
[TBL] [Abstract][Full Text] [Related]
19. Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs.
Kobayashi S; Sakai T; Dalrymple PD; Wood SG; Chasseaud LF
Arzneimittelforschung; 1993 Dec; 43(12):1367-77. PubMed ID: 8141830
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography.
Jehl F; Quoix E; Leveque D; Pauli G; Breillout F; Krikorian A; Monteil H
Cancer Res; 1991 Apr; 51(8):2073-6. PubMed ID: 1849042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
